Stem cell research holds huge potential for medicine plus human health. In particular, human embryonic stem cells (ESCs), with their ability to turn into any cell in the human body, are crucial to the future prevention and treatment of disease.
One set or two? Diploid versus haploid cells
Most of the cellular material in our body are diploid, which means they carry 2 sets of chromosomes — one from each parent. So far, scientists have only succeeded in creating haploid wanting stem cells — which contain a single set of chromosomes — in non-human mammals such as mice, rats and monkeys. However , scientists have long sought to isolate plus replicate these haploid ESCs in humans, which would permit them to work with one set of human chromosomes as opposed to a mixture through both parents.
This milestone was lastly reached when Ido Sagi, working as a PhD pupil at the Hebrew University of Jerusalem’s Azrieli Center to get Stem Cells and Genetic Research, led research that will yielded the first successful isolation and maintenance of haploid wanting stem cells in humans. Unlike in mice, these types of haploid stem cells were able to differentiate into many other cellular types, such as brain, heart and pancreas, while keeping a single set of chromosomes.
With Prof. Nissim Benvenisty, Director of the Azrieli Center, Sagi showed this new human stem cell type will play an important part in human genetic and medical research. It will help our understanding of human development — for example , why all of us reproduce sexually instead of from a single parent. It will create genetic screening easier and more precise, by allowing the particular examination of single sets of chromosomes. And it is already allowing the study of resistance to chemotherapy drugs, with implications intended for cancer therapy.
Diagnostic kits meant for personalized medicine
Based on this study, Yissum, the Technology Transfer arm of the Hebrew College, launched the company New Stem, which is developing a diagnostic package for predicting resistance to chemotherapy treatments. By amassing an extensive library of human pluripotent stem cells with different variations and genetic makeups, NewStem plans to develop diagnostic packages for personalized medication and future therapeutic and reproductive : products.
2017 Kaye innovation Honor
In recognition of his function, Ido Sagi was awarded the Kaye Innovation Honor for 2017.
The Kaye Innovation Honours at the Hebrew University of Jerusalem have been awarded each year since 1994. Isaac Kaye of England, a notable industrialist in the pharmaceutical industry, established the awards in order to encourage faculty, staff and students of the Hebrew College to develop innovative methods and inventions with good industrial potential, which will benefit the university and society.
Ido Sagi received BSc summa cum laude in every area of your life Sciences from the Hebrew University, and currently pursues the PhD at the laboratory of Prof. Nissim Benvenisty in the university’s Department of Genetics in the Alexander Silberman Start of Life Sciences. He is a fellow of the Adams Fellowship of the Israel Academy of Sciences and Humanities, and has recently received the Rappaport Prize for Superiority in Biomedical Research. Sagi’s research focuses on studying hereditary and epigenetic phenomena in human pluripotent stem tissue, and his work has been published in leading scientific magazines, including Nature , Character Genetics and Cell Originate Cell .
Materials provided by Hebrew University of Jerusalem . Note: Content may be edited for style and duration.